Estimating the Budget Impact of Switching from Bortezomib Intravenous (Iv) to Bortezomib Subcutaneous (Sq) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Mexico

Abstract

Authors

EA Wehler S Kowal A Hernandez-Garduno L Danese de los Santos JA de Anda P Anaya J Munakata L Gonzalez